Lapatinib

Lapatinib__EGFR, HER2 inhibitor Atrasentan (hydrochloride)

Product Name	Lapatinib
Description	EGFR, HER2 inhibitor
Purity	>99%
CAS No.	231277-92-2
Molecular Formula	C29H26ClFN4O4S
Molecular Weight	581.1

Storage Temperature	-20ºC
Shipping Temperature	Shipped Ambient
Product Type	Inhibitor
Solubility	Solubility in water is 0.007 mg/ml and in 0.1N HCl is 0.001 mg/ml at 25° C
Source	Synthetic
Appearance	Yellow crystalline solid
SMILES	C2=C1C(=NC=NC1=CC=C2C3=CC=C(O3)CNCCS(=O)(=O)C)NC4=CC=C(C(=C4)Cl)OCC5=CC=CC(=C5)F
InChI	InChI=1S/C29H26ClFN4O4S/c1-40(36,37)12-11-32-16-23-7-10-27(39-23)20-5-8-26-24(14-20)29(34-18-33-26)35-22-6-9-28(25(30)15-22)38-17-19-3-2-4-21(31)13-19/h2-10,13-15,18,32H,11-12,16-17H2,1H3,(H,33,34,35
InChIKey	BCFGMOOMADDAQU-UHFFFAOYSA-N
Safety Phrases	Classification: Not a hazardous substance or mixture. Safety Phrases: S22 – Do not breathe dust. S24/25 – Avoid contact with skin and eyes. S36/37/39 – Wear suitable protective clothing, gloves and eye/face protection.
Cite This Product	Lapatinib (StressMarq Biosciences Inc., Victoria BC CANADA, Catalog # SIH-459)

Alternative Names	N-3-chloro-4-(3-fluorophenyl)methoxyphenyl-6-5-(2-methylsulfonylethylamino)methylfuran-2-ylquinazolin-4-amine
Research Areas	Cancer, Apoptosis, Cancer Growth Inhibitors, Cell Signaling, Growth Factor Receptor Inhibitors
PubChem ID	208908
Scientific Background	Lapatinib is a tyrosine kinase inhibitor. Specifically, it interrupts the ErbB/neu and epidermal growth factor receptor (EGFR) pathways. It is an antineoplastic agent used in breast cancer research. In solid tumor cells, Lapatinib binds to the ATP-binding pocket of the protein kinase domains on EGFR/ErbB, preventing self-phosphorylation.
References	1. Chien A.J., et al. (2014) J. Clin. Oncol: J. Am. Clin. Oncol. 32(14): 1472–1479. 2. Dahal B.K., et al. (2010) Am. J. Resp. Critical Care Med. 181(2): 158–167.